A high level of blood IFN-α concentration is also characteristic of autoimmune diseases like dermatomyositis (DM), scleroderma, and systemic lupus erythematosus (SLE).6, 7, 8 In SLE, the systemic level of IFN-α is used as biomarker of disease activity and identifies patients at risk of relapse during remission, making drugs targeting this pathway promising therapeutic options. Here, IFNA2 is linked to scleroderma.